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Abstract 
 Objective: Research describing the uptake and geographic variability in the 
human papillomavirus (HPV) vaccine is limited and has relied on data collected from 
large national surveillance programs. The overarching goal of this dissertation was to 
estimate the uptake of the HPV vaccine at the ZIP code level and to determine if uptake 
varied geographically. 
 Methods: In Manuscript 1, we recruited 1,003 men and women via a targeted 
Facebook advertisement campaign to complete an online survey about HPV vaccination 
practices.  In Manuscript 2, we examined the geographic variation in HPV vaccine uptake 
using ZIP code level data from 760 individuals nested within 99 ZIP codes surrounding 
the downtown area of Minneapolis, Minnesota to identify predictors of vaccination while 
accounting for spatial dependence.  In Manuscript 3, women aged 21-30 years were 
recruited online to participate in either (1) self-collected testing for HPV and an online 
survey, or (2) an online survey regarding their perceptions of self-collected testing for 
HPV infection. A variety of statistical methods were used to answer our research 
questions including logistic regression and proper spatial conditional autoregressive 
(CAR) models. 
 Results: In Manuscript 1, we found that receipt of ≥1 dose of HPV vaccine for 
women was 65.6% and 12.5% for men, which differs from previously reported 
Minnesota state level estimates (53.8% for young women and 20.8% for young men) and 
from national estimates (34.5% for women and 2.3% for men).  In Manuscript 2, HPV 
vaccination was found to exhibit strong spatial dependence ( ). Accounting 
for spatial dependence, older age, male gender, and liberal political preference were 
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found to be significant predictors of HPV vaccination.  In Manuscript 3, we found that 
self-collection was acceptable to women, and that women who self-collected a sample 
reported more favorable attributes of self-collection compared to women who only 
participated in the online survey. 
 Conclusions: Local estimates to assess the variation in HPV vaccine uptake are 
needed, as these estimates differ considerably from those obtained using survey data that 
is aggregated to the state or federal level.  In addition, studies that examine geographic 
variation in HPV vaccination need to account for spatial dependence in order to identify 
predictors associated with vaccine receipt.  Online recruitment and at home screening 
methods have the potential to engage women in screening by offering an approach that 
might be more acceptable to women of different backgrounds.   
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Chapter 1. Overview of the Dissertation 
1.1 Statement of the Problem 
 Human papillomavirus (HPV) infections in men and women present a tremendous 
public health burden.  Effective prevention and screening strategies (i.e. vaccination 
against HPV, HPV testing and Pap test-based screening) are available to reduce HPV-
associated disease morbidity and mortality. However, HPV vaccination has not been 
accepted as quickly as was originally anticipated, with significant variation at both the 
state and local level. Moreover, vaccination and screening are less likely to be used by at-
risk populations (e.g. people living in poverty, racial minorities, or immigrants).  
Importantly, these are the populations that may benefit the most from HPV vaccination 
and cancer screening since they are at the highest risk for HPV-associated disease. As a 
result, health disparities continue to exist and adversely affect certain groups of men and 
women.  
The CDC currently monitors HPV vaccine coverage and cervical cancer screening 
practices by piecing together results from five national health surveys  that vary greatly in 
terms of their sampling procedures, their intended target populations, the type of data that 
is collected, and the expected uses of the collected information.  Importantly, sampling in 
these surveys is such that variations at a local level (i.e. between counties or zip codes) 
cannot be adequately assessed.  Additionally, these surveys have also been directed 
towards girls and have not inquired about the HPV vaccination practices of boys. These 
data are needed, as an ongoing concern is that if women who do
 
not participate in 
screening are also those who are less likely to be vaccinated, disparities will continue to 
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occur and potentially grow. Research is needed in order to determine whether women 
who are vaccinated are also being screened, and vice versa.   
The current scarcity of data at local levels also limits researchers’ ability to study 
the associations and patterns of HPV vaccination among youth.  The only method that is 
currently available for assessing HPV vaccination uptake involves the patchwork of 
surveillance systems mentioned above which lack geographic resolution.  Thus, it is not 
currently possible to identify detailed HPV vaccination patterns and their relationship to 
incident infections to estimate the long-term health effects of vaccination efforts.  
1.2 Specific Aims 
 This research aims to identify ZIP codes within the Twin Cities Metropolitan 
Area where screening and vaccination participation varies.  The goals of this dissertation 
research were to obtain information regarding cancer screening and HPV vaccination 
from men and women at the local level, to evaluate the associations of these behaviors by 
place of residence, and to determine the feasibility of recruiting participants online to 
participate in self-collected HPV testing.  In particular, the following research questions 
and aims were addressed: 
1) Will men and women participate in online research regarding HPV vaccination 
and cancer screening practices?  
Aim 1: Demonstrate the feasibility and cost-effectiveness of recruiting men and 
women for health research through the Internet. 
2) Does the prevalence of HPV vaccination among men and women at a local level 
differ from state and national level estimates? 
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Aim 2: Estimate the prevalence of HPV vaccination among men and women in 
the Twin Cities Metropolitan Area. 
3) Does the pattern of HPV vaccination uptake differ after accounting for spatial 
dependence?  
Aim 3: Describe and evaluate the distribution of HPV vaccination uptake by ZIP 
code in the Twin Cities Metropolitan Area.   
4) Will women participate in self-collected HPV testing after being recruited on the 
Internet? 
Aim 4: Obtain self-collected vaginal samples for HPV testing from women 
recruited on the Internet to determine the feasibility of self-collected screening in 
this population and to determine the potential for providing underserved women 
with cancer screening via Internet recruitment. 
1.3 Organization of the Dissertation 
 This dissertation consists of three inter-related manuscripts.  A detailed 
background of the disease burden and epidemiology of HPV will be discussed, followed 
by the three manuscripts which will be submitted for publication. Below, the research 
questions and specific aims for each manuscript are presented. 
 Manuscript 1 
 Manuscript 1 investigated the potential of using an online survey to obtain HPV 
vaccination and cancer screening information from men and women in the greater Twin 
Cities Metropolitan Area.  To this end, the Survey of Minnesotans About Screening and 
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Health (SMASH) study was developed. The primary research questions and specific aims 
were:  
1) Will men and women participate in online research regarding HPV vaccination 
and cancer screening practices?  
Aim 1: Demonstrate the feasibility and cost-effectiveness of recruiting men 
and women for health research through the Internet. 
2) Does the prevalence of HPV vaccination among men and women at a local 
level differ from state and national level estimates? 
Aim 2: Estimate the prevalence of HPV vaccination among men and women 
in the Twin Cities Metropolitan Area. 
Manuscript 2 
Manuscript 2 examined the pattern of HPV vaccine uptake at the ZIP code level 
for 760 men and women residing within a 25-mile radius of downtown Minneapolis, 
Minnesota.  The primary research question and specific aim was:  
3) Does the pattern of HPV vaccination uptake differ after accounting for spatial 
dependence?  
Aim 3: Describe and evaluate the distribution of HPV vaccination uptake by 
ZIP code in the Twin Cities Metropolitan Area.   
Manuscript 3 
Manuscript 3 builds on the results of manuscripts 1 and 2. A subset of the women 
who participated in the SMASH study were invited to either self-collect a vaginal sample 
for HPV DNA testing or to respond to an online survey regarding their perceived 
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acceptability of self-collected screening for HPV. Specifically, the primary research 
question and specific aim of this manuscript was: 
4) Will women participate in self-collected HPV testing after being recruited on 
the Internet? 
Aim 4: Obtain self-collected vaginal samples for HPV testing from women 
recruited on the Internet to determine the feasibility of self-collected screening 
in this population and to determine the potential for providing underserved 
women with cancer screening via Internet recruitment. 
This dissertation demonstrates the efficiency and feasibility of using the Internet 
to collect public health data and to recruit participants for interventions. This dissertation 
is the first study to examine the spatial pattern of HPV vaccine uptake at the ZIP code 
level, and to recruit women via the Internet to participate in self-collected HPV DNA 
testing. This dissertation suggests that specific locations can (and should) be identified in 
order to maximize future intervention and vaccination strategies designed to reduce HPV-
associated disease. In addition, this dissertation suggests that online recruitment and 
screening approaches may be used to facilitate targeted screening among high-risk sub-
populations, including under-screened and underprivileged women, to reduce the burden 
of HPV disease. 
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Chapter 2. Background and Epidemiology of HPV 
2.1 General Background  
 Human papillomavirus (HPV) is the most common sexually transmitted infection 
in the U.S. [1], and is the necessary cause of cervical cancer and genital warts [2].  There 
is increasing evidence that other cancers are also associated with HPV infection (e.g. 
anogenital and oropharyngeal cancers) [3-4]. In total, it is estimated that 5.2% of cancers 
in men and women worldwide are attributable to HPV [5].  
 It is known that HPV infections among men and women present a tremendous 
public health burden; however, there remain major gaps in our understanding of how 
many HPV infections occur, and to what extent they will progress into serious diseases. 
Although screening is highly effective in reducing the incidence of cervical cancer, 
participation continues to vary between ethnic and socioeconomic groups [6]. More than 
60% of cervical cancer cases in the U.S. occur in medically underserved and 
underscreened populations [7]. Additionally, HPV-associated cervical cancer rates appear 
to follow a unique pattern across the United States, with lower observed rates in the 
Pacific Northwest, Upper Midwest, and small Northeastern states, and significantly 
higher cervical cancer rates in the South and Central Eastern states (see Figure 2.1) [8]. In 
prior research conducted as part of my Master’s thesis, I showed that cervical cancer rates 
also vary considerably within the state of Minnesota by county (refer to Figure 2.2) [9].   
 The FDA has licensed two HPV vaccines (quadrivalent Gardasil® in 2006 and 
bivalent Cervarix® in 2009) that protect against HPV types 16 and 18, the most common 
oncogenic HPV types [10-11]. The Advisory Committee on Immunization Practices 
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(ACIP) recommends using either vaccine for routine vaccination of boys and girls aged 
11 or 12 years old, with catch-up vaccination recommended for those aged 13 to 26 years 
[12-14]. Although these vaccines have been shown to be safe and effective, uptake has 
been far lower than expected [15]. As of 2012, in the United States approximately 53.8% 
(95% CI, 51.9% to 55.7%) of girls aged 13 to 17 in the United States had received at least 
1 dose of HPV vaccine (either the quadrivalent or bivalent vaccine). Of those girls who 
had at least one HPV dose, only 66.7% (95% CI, 64.1% to 69.3%) had received the 
complete three-dose regimen [15].   
 Uptake within the state of Minnesota is similar to that reported nationally with 
55.5% (95% CI, 45.6% to 65.4%) of girls reporting receipt of at least 1 dose of the HPV 
vaccine, and only 66.4% (95% CI, 50.1% to 82.7%) of those girls reporting receipt of the 
complete three-dose regimen. Thus, HPV vaccine coverage (completed all three doses) in 
adolescent girls aged 13 to 17 years in Minnesota is estimated to be 35.1% (95% CI, 26.0 
to 44.2%), compared to 34.8% (95% CI, 33.2% to 36.4%) nationally in 2011 [16]. 
Nevertheless, the 2011 three-dose coverage national estimate among girls aged 13 to 17 
years falls well short of the Healthy People 2020 target of 80% for girls aged 13 to 15 
years [17] and is much lower than uptake reported in Canada (50-85%), Panama (67%), a 
region of Mexico (67%), the United Kingdom (83%), and Australia (>70%) [18-20]. Also 
by way of contrast, estimates from a simulation study of the Australian population project 
that an HPV vaccine uptake of approximately 80% would be necessary to achieve herd 
immunity at the population level [21]. Although this study was based on factors specific 
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to Australia, the large discrepancy in actual uptake and projected uptake to achieve herd 
immunity is likely to be similar in the United States. 
 HPV vaccination uptake in boys and girls also appears to differ among 
sociodemographic groups. In 2011, Hispanics (65.0%, 95% CI, 60.9% to 69.1%) were 
statistically significantly more likely than non-Hispanic whites (47.5%, 95% CI, 45.6% to 
49.4%) to have received one or more HPV vaccine doses [16]. Boys and girls who were 
insured privately, publicly or through the free vaccine program Vaccines for Children 
(VFC) were much more likely (38-55%) than the uninsured (6.4%) to have received one 
or more HPV vaccine doses [16].  
 The CDC currently monitors HPV vaccine coverage and cervical cancer screening 
practices by piecing together results from five national health surveys (National Survey 
of Family Growth (NSFG), the National Immunization Survey [22], the National Health 
and Nutrition Examination Survey (NHANES), the National Health Interview Survey 
(NHIS), and the Behavioral Risk Factor Surveillance System (BRFSS)).  These surveys 
vary greatly in their sampling procedures, their intended target populations, the type of 
data that is collected, and the expected uses of the collected information.  As shown in 
Table 2.1, four of these surveys ask respondents about either cervical cancer screening or 
the HPV vaccine, but fail to ask questions on both topics.  Only one survey (BRFSS) asks 
questions regarding vaccination and screening practices in the same population of 
respondents.  However, the information from BRFSS is restricted to four questions and 
does not inquire about potential barriers to screening and future vaccination plans. 
Importantly, sampling in these surveys is such that variations at a local level (i.e. between 
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counties or zip codes) cannot be adequately assessed.  Additionally, these surveys have 
also been directed towards girls and have not inquired about the HPV vaccination 
practices of boys. These data are needed, as an ongoing concern is that if women who do
 
not participate in screening are also those who are less likely to be vaccinated, disparities 
will continue to occur and potentially grow. Research is needed in order to determine 
whether women who are vaccinated are also being screened, and vice versa.   
The current scarcity of data at local levels also limits researchers’ ability to study the 
associations and patterns of HPV vaccination among youth.  The only method that is 
currently available for assessing HPV vaccination uptake involves the patchwork of 
surveillance systems mentioned above which lack geographic resolution.  Thus, it is not 
currently possible to identify detailed HPV vaccination patterns and their relationship to 
incident infections to estimate the long-term health effects of vaccination efforts.  
2.2 HPV Burden of Disease 
 
 Approximately 79 million American men and women are currently infected with 
HPV, with an estimated 14 million newly infected men and women each year [23]. HPV 
is recognized as a necessary cause of cervical cancer, and is known to cause more than 
80% of anal cancer cases in men and women [10]. HPV is also associated with several 
other cancers, in addition to anogenital condyloma (genital warts), respiratory 
papillomatosis, and intraepithelial neoplasia [24].   
 The most common HPV-associated mortality is cancer of the cervix, and most of 
the attention of clinicians and researchers has appropriately been directed toward this 
disease and its precursors [25]. However, HPV infection in men is of great importance as 
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well given that sexual transmission is the primary mode of spread to women [26-28].  
Further, in the past decade, research findings have led to the recognition that HPV also 
causes disease in men [24]. Several cancers of the anogenital tract and upper aero-
digestive tract, and their precursor lesions in men are now attributed to infection with 
sexually transmitted HPV [11, 29]. HPV-related outcomes have also been found to occur 
much more frequently among men who have sex with men, and in men infected with HIV 
compared to heterosexual men [25, 30-36]. Research is needed to more adequately 
describe the HPV infection rates among men, and to identify key risk factors that can 
account for the disparity of disease occurrence in male populations.  Understanding HPV 
infections in men is therefore critical in order to reduce the morbidity associated with 
HPV diseases in men, as well as to reduce the risk of HPV transmission to women. 
2.3 Epidemiology of HPV 
 
 There are more than 100 different types (strains) of HPV, with over 40 HPV types 
that infect the genital areas of men and women, most often during vaginal or anal sex [11, 
37]. HPV types differ as to which type of epithelium they invade, their ability to evade 
immune detection, to resist immune defense mechanisms, and their oncogenic 
capabilities. HPV types are categorized into two groups based on their oncogenic 
potential: high-risk (HR-HPV) and low-risk (LR-HPV).  LR-HPV types, such as types 6 
or 11, can cause 1) benign or low-grade abnormalities of the cervix, 2) anogenital warts, 
and 3) recurrent respiratory papillomatosis (RRP) [38]. HR-HPV types, including types 
16 and 18, can cause intraepithelial neoplasia of the anogenital region, including cervical, 
vulvar, vaginal, penile, and anal cancers as well as some oropharyngeal cancers [35, 39-
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40].  HPV types 16 and 18 are considered the most highly oncogenic types as they 
collectively account for approximately 72% of HPV-related cancers [35].  
 HPV infections are primarily acquired early in sexual life [41-42].  Rates of 
incident HPV infection are high following first sexual intercourse [43-45].  Risk factors 
associated with HPV infection are related to sexual behavior.  In particular, early age of 
first sexual relationships, high numbers of lifetime sexual partners, and sexual contacts 
with high risk individuals (for men, frequent contact with prostitutes and for women, 
frequent contacts with men with multiple sexual partners) have shown to be associated 
with HPV infection [46]. However, male circumcision and consistent use of condoms are 
factors that can reduce (but do not completely prevent) the risk of HPV transmission 
between sexual partners [47-48]. 
 The prevalence of HPV infections is not only influenced by sexual activity, but 
also varies by age and geography, as has been shown by the International Agency for 
Research on Cancer (IARC) and others [49-51]. Several international studies have 
demonstrated that HPV acquisition and incidence peaks in young women and tends to 
decline with age [45, 52-54].  Whether age is also related to the duration of the infection 
remains to be seen. Several studies have reported that there is no influence of age on the 
rate of HPV clearance. Whereas other studies have reported lower clearance rates with 
increasing age, and some have shown fast rates of clearance in older women [55-59].  
These contradictory results are likely due to variations in study populations with respect 
to age, geography, the type of HPV DNA test used, and other risk factors related to HPV-
related outcomes. 
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 In the United States, studies using HPV DNA testing of asymptomatic women in 
the general population estimate the prevalence of HPV infection to be between 2% and 
44% [60]. However, prevalence of HPV infection is estimated to be the highest for both 
men and women during their early 20’s [60-61]. Among U.S. college students, HPV 
prevalence has been estimated to be 24% to 55% in women and 26% to 65% in men [61]. 
Due to the common transmission route, many HPV types tend to be transmitted together, 
which results in a high proportion of concurrent infections with several types of HPV 
[62-64]. In addition, multiple HPV types have been detected in as many as 20% of 
women infected with HPV [65].  
It is important to emphasize that most HPV infections are asymptomatic, 
transient, and are cleared naturally without treatment [11, 60, 66]. The average duration 
of HPV infection is estimated to last 4.3 months for LR-HPV and 9.8 months for HR-
HPV among college aged women in the U.S. [67-68].  As a result, aggressive annual 
testing and screening for HPV infection in the general population would be extremely 
expensive and impractical in order to reduce HPV-associated outcomes.  Moreover, an 
aggressive strategy of annual screening could lead to unnecessary procedures, treatments, 
and triage of infections that would otherwise clear naturally [69-70]. Therefore, the 
current strategies to limit the long-term effects of HPV rely upon early detection and 
screening for disease outcomes, with optional testing for HPV infection recommended in 
women ≥ 30 years in order to extend cervical cancer screening intervals.  
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2.4 Vaccination Against HPV 
 
 Two vaccines have been approved for use in the U.S. that are targeted at 
preventing HPV infection.  Gardasil® (Merck & Co., Whitehouse Station, NJ USA) was 
approved for use by the FDA in 2006 [10, 71]. The second vaccine, Cervarix® 
(GlaxoSmithKline Biologicals, Rixensart, Belgium), was approved in the fall of 2009 
[12]. Gardasil® and Cervarix® both protect against HPV types 16 and 18.  Gardasil® is 
also designed to protect against types 6 and 11, the two HPV types that cause the 
majority of anogenital warts [11]. Data from clinical trials have shown that both vaccines 
prevent vaccine type-related cervical precancers [71-72], and the quadrivalent vaccine 
has also been shown to prevent vaginal, vulvar, and anal precancers [73-74].  This 
evidence suggests that the vaccines also confer protection against HPV-related genital 
lesions in males aged 16 to 26 years, not just in women as was previously indicated [30-
31].  
 Although these vaccines have shown to be safe and effective at preventing HPV 
infection thus far, uptake among the general population has been lower than expected (as 
described above) [75]. Due to the slow uptake of the HPV vaccine among women and the 
significant potential for preventing infection in men, the Advisory Committee on 
Immunization Practices (ACIP) recently amended their recommendations to include the 
use of the quadrivalent vaccine Gardasil® for use in young men [75]. The potential health 
impact and benefits that will come from this new recommendation have not yet been fully 
evaluated.  One study recently estimated that the overall annual direct medical cost 
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burden of preventing and treating HPV was $8.0 billion (not including HPV vaccination 
or HPV testing) [76].   
2.5 Detection of HPV 
  
 Randomized controlled trials conducted over the last decade suggest that HPV 
DNA testing could be a more effective approach to the early detection of cervical cancer 
for women over the age of 30 years than cytology alone [77], and that HPV self-
collection (i.e., self-collection of vaginal specimens for HPV DNA testing) may be a 
feasible alternative to traditional clinician-collected cytology screening.  Testing for HPV 
is more sensitive than cytology for detecting high-grade squamous intraepithelial lesions 
(HSIL) and invasive cervical cancer [78-88].   
 Sampling both the cervix and vulva-vagina, traditionally performed by a trained 
clinician, is the most effective method for detecting HPV infections in the female genital 
tract [89-90].  However, in recent years numerous studies have shown that self-collected 
samples are as sensitive as healthcare provider-collected samples for detection of HPV 
DNA [89, 91].  A recent meta-analysis of 18 studies reported that a high level of 
concordance of 0.87 (95%CI, 0.82 to 0.91) between self and physician sampling was 
obtained for detection of HPV DNA (kappa 0.66, 95%CI, 0.56 to 0.76) [90]. The 
prevalence difference of any HPV DNA between sampling methods was −0.5 (95%CI, 
−2.8 to 1.8) lower for self-collected samples. Results were similar when restricting the 
analysis to HR-HPV. Although most previous studies have been based on in-clinic self-
collected samples that were obtained just prior to the normal patient visit, a recent study 
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examined at-home as well as in-clinic self-collected vaginal and clinician-collected 
cervical samples from a total of over 600 women age 18 to 25. Agreement between self-
collected vaginal and clinician-collected combined cervical/vulva-vaginal samples was 
excellent [89].  Other studies confirm the accuracy and acceptability of self-sampling 
[92-93]. Previous studies also suggest that this at home approach is highly acceptable to 
women participating in screening programs [94]. 
 In summary, as a screening tool, self-collected samples may be comparable to 
clinical settings in terms of test accuracy, and may be more feasible which could increase 
screening coverage in the general population (and notably distinct underscreened 
populations may benefit from targeted efforts to use self-collected sampling) than 
clinician-performed sampling [89].  Self-sampling would remove the need for a clinician 
and encourage screening coverage among women not attending clinic based cervical 
cancer screening.  Furthermore, with HPV typing and the availability of prophylactic 
HPV vaccines, it is important to determine the population-level impact of vaccines on the 
prevalence of HPV types that are and are not targeted by vaccines.   
2.6 Conclusion 
 
 The tremendous disease burden due to HPV infections and the potential benefits 
of vaccination are only beginning to be understood.  In order to mitigate major gaps in 
knowledge regarding HPV vaccines, it is imperative that data be collected at local levels 
to better estimate their impact and reach.  Understanding the patterns of where HPV-
related diseases occur will help shape HPV prevention strategies (i.e. vaccine campaigns 
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and policies) and assist in predicting the actual burden of HPV-related disease.  Using 
modern methods and venues, such as self-collected sampling and HPV DNA tests, to 
reach underserved men and women is essential in order to improve screening uptake and 
increase the treatment of disease.  These modern methods provide more flexibility than 
traditional clinical settings and permit targeted strategies toward underscreened men and 
women.  These tailored approaches will have the greater impact as they can focus on the 
at-risk and underserved populations instead of doing more among the majority of the 
population who are already at a reduced risk of HPV-associated diseases.  
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 Figure 2.1. Map of HPV-associated cervical cancer rates by state, 2012. 
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Figure 2.2. Crude rates and spatially clustered rate categories of HPV-associated cancers 
in men and women by county in Minnesota, 1998-2007. 
 
Clustered values can range from 0 to 1, with values closer to 1 indicating clustering of high rate values (red) and values 
closer to 0 representing clusters for low rate values (blue). Coordinate System: NAD 1983 HARN StatePlane 
Minnesota Central FIPS 2202. 
 
 
 
 
Table 2.1. Comparison of five national surveys regarding cervical cancer screening and 
HPV vaccination questions among women. 
 
Survey  
Age of Female 
Respondents 
Cervical  
Cancer 
Screening 
HPV Vaccine 
Receipt 
HPV Vaccine 
Barriers & 
Intentions 
Data Extent 
NHANES 14-59 yrs No Yes No State/Nation 
NIS 13-17 yrs No Yes Yes State/Nation 
NSFG 15-44 yrs No  Yes Yes State/Nation 
NHIS 18-49 yrs  Yes No No Nation
a
  
BRFSS 18-49 yrs Yes Yes Yes State/Nation 
aSome state level data are available 
Abbreviations used: NHANES, National Health and Nutrition Examination Survey; 
NIS, National Immunization Survey; NSFG, National Survey of Family Growth; 
NHIS, National Health Interview Survey; BRFSS, Behavioral Risk Factor 
Surveillance System 
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Chapter 3. Manuscript 1: Facebook Recruitment for an Online Survey to Estimate 
Geographic Variation in Human Papillomavirus Vaccine Uptake in Men and 
Women 
3.1 Overview of Manuscript 1 
 
 The objective of Manuscript 1 was to describe HPV vaccination and cancer 
screening practices in the Twin Cities Metropolitan Area.  Currently, no data has been 
collected that captures HPV vaccination status, cancer screening practices, and barriers to 
HPV vaccination and cancer screening services within the same survey instrument.  This 
is important because current strategies are based on a patchwork of incomplete data from 
several surveillance systems. Obtaining information on cancer screening practices and 
HPV vaccination within the same study population may lead to a better understanding of 
who is not receiving these services and where these services could be used to reduce 
HPV-related disease.   
 The goal of this pilot project was to analyze self-reported questionnaire data from 
the Survey of Minnesotans About Screening and HPV (SMASH) Study to better 
understand uptake of the HPV vaccine and cancer screening, and characteristics 
associated with not receiving these services.  The SMASH Study recruited men and 
women in Minnesota via Internet-based social media to complete an online survey 
regarding HPV vaccination status, cancer screening practices and potential barriers to 
receiving these services based on the participants’ place of residence.  The aim of this 
project was to demonstrate the feasibility and cost of using the Internet to recruit and 
administer a survey to a representative sample from the Twin Cities Metropolitan Area 
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(Aim 1). Manuscript 1 also describes the characteristics of study participants and 
estimates the prevalence of HPV vaccination in the Twin Cities Metropolitan Area and 
compares them to state and national level estimates (Aim 2).  
3.2 Summary 
 Background: Federally funded surveys of human papillomavirus (HPV) vaccine 
uptake are important for pinpointing geographically based health disparities.  Although 
national and state level data are available, local (i.e. county and zip code level) data are 
not due to small sample sizes, confidentiality concerns, and cost.  Local level HPV 
vaccine uptake data may be feasible to obtain by targeting specific geographic areas 
through social media advertising and recruitment strategies, in combination with online 
surveys. 
 Objective: To use Facebook based recruitment and online surveys to estimate 
local variation in HPV vaccine uptake among young men and women in Minnesota. 
 Methods: From November 2012 to January 2013, men and women were recruited 
via a targeted Facebook advertisement campaign to complete an online survey about 
HPV vaccination practices.  The Facebook advertisements were targeted to recruit men 
and women by location (25 mile radius of Minneapolis, Minnesota, United States), age 
(18-30 years), and language (English).  
Results: Of the 2,079 men and women who responded to the Facebook 
advertisements and visited the study website, 1,003 (48.2%) enrolled in the study and 
completed the survey. The average advertising cost per completed survey was $1.36.  
Among those who reported their ZIP code, 881 out of 972 (90.6%) of the participants 
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lived within the a priori geographically defined study area. Receipt of ≥1 dose of HPV 
vaccine was reported by 351 of 535 women (65.6%), and by 45 of 361 men (12.5%).  
These results differ from previously reported Minnesota state level estimates (53.8% for 
young women and 20.8% for young men) and from national estimates (34.5% for women 
and 2.3% for men).   
Conclusions: This study shows that recruiting a representative sample of young 
men and women based on county and zip code location to complete a survey on HPV 
vaccination uptake via the Internet is a cost-effective and feasible strategy.  This study 
also highlights the need for local estimates to assess the variation in HPV vaccine uptake, 
as these estimates differ considerably from those obtained using survey data that is 
aggregated to the state or federal level.  
3.3 Introduction   
 Human papillomavirus (HPV) is the most common sexually transmitted infection 
in the U.S. [1], and is the necessary cause of cervical cancer [2].  HPV infections are also 
associated with other cancers (e.g. anogenital and oropharyngeal) as well as genital warts 
[3-4]. In total, it is estimated that 5.2% of cancers in men and women worldwide are 
attributable to HPV [35].  
 Two vaccinations against HPV infection are currently licensed in the U.S.  The 
vaccinations were originally licensed for use in girls, but as of October 2011, the 
Advisory Committee on Immunization Practices (ACIP) extended their recommendation 
of the quadrivalent vaccine to include both boys and girls aged 11 or 12 years old [12, 
14].  However, vaccine uptake has been far lower than expected, with only about half of 
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eligible young women receiving at least one dose of the vaccine [15]. Initiation of the 
HPV vaccine has been shown to be higher among minority adolescent girls, however 
completion of the three-dose series is substantially lower among blacks and Hispanics 
compared to whites [95].  Although male vaccination data are very limited (due to a later 
date of approval of the HPV vaccine for boys), racial and income differences in terms of 
vaccine series initiation and completion have also been observed among adolescent boys 
[96].   
 Previous research on HPV vaccine coverage has utilized publicly available data 
from five national health surveys (National Survey of Family Growth, National 
Immunization Survey - Teen, National Health and Nutrition Examination Survey, 
National Health Interview Survey, and the Behavioral Risk Factor Surveillance System) 
[97-101]. These surveys are designed to gather information on a variety of health topics 
and only ask a few questions regarding HPV vaccination. However, none of these 
surveys addresses HPV vaccination and related practices such as cervical cancer 
screening and potential barriers to screening or vaccination. In addition, due to the small 
number of responses in many geographic areas, local data from these surveys are 
routinely suppressed and aggregated to state boundaries in order to protect the 
confidentiality of survey respondents which means that variations at a local level (i.e. 
between counties or ZIP codes) cannot be adequately assessed.  Further, these surveys 
have, to date, primarily surveyed adolescent girls; HPV vaccination practices of 
adolescent boys are limited [15].  
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 The Internet provides a unique point of contact to reach young adults for health 
research.  Several studies have demonstrated that Internet-based research can be used to 
elicit high response rates at a fraction of the cost of traditional recruitment methods [102-
104].  In addition, it has been shown that when compared to in-person interviews, 
Internet-based surveys have the potential to reach more respondents, include otherwise 
inaccessible populations, and to reduce bias in responses as respondents may be willing 
to report more sensitive information online compared to in-person interviews [105-110].
  
A number of studies have also shown that recruitment via Facebook (the leading social 
media site with more than one billion active users worldwide) can be used to enroll 
representative samples of the general population [102, 111-114].
  
This combination of 
reach, utility, and reduced cost indicates that social media networks can be a cost-
effective medium for research.  
 The objective of this study was to estimate HPV vaccination practices among a 
local population of young adult men and women using an Internet-based recruitment 
strategy.   
3.4 Research Methods 
Study Population 
Men and women from Minnesota were surveyed about their HPV vaccination 
practices via the Internet from November 21, 2012 through January 31, 2013. Participants 
were English-speaking, aged 18 to 30 years, had a Facebook account, and resided in the 
greater Twin Cities Metropolitan Area (i.e. within 25 miles of downtown Minneapolis, 
MN).  This age range was used to target men and women who were eligible to receive the 
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HPV vaccine, participate in cervical cancer screening (women), and able to provide 
informed consent.  The Twin Cities Metropolitan Area was selected due to heterogeneity 
of HPV-related cancer incidence rates exhibited in this area during the past 15 years, the 
high concentration of colleges and universities, and the large population of 18 to 30 year 
olds residing in this area [9]. The University of Minnesota Institutional Review Board 
approved this study.
 
Facebook Recruitment Campaign 
Participants were recruited online via Facebook advertisements (Figure 3.1).  
Tailored advertisements were used to target Facebook users that had profiles that 
matched the study inclusion criteria.  These advertisement criteria were adjusted as 
needed to achieve a balanced sample of participants by ZIP code.  Facebook uses an 
advertisement algorithm that automatically selects the best advertisement to display based 
on its performance and the advertiser’s bid [115].  All advertisements were approved by 
Facebook.  For this study, multiple advertisements were submitted for auction 
simultaneously to create a continuous recruitment window in the event that a particular 
advertisement performed poorly.  Bidding prices and advertisement availability 
(advertisements can be paused and released at the discretion of the advertiser) were 
monitored daily and adjusted as necessary until the intended number of completed 
questionnaires was obtained.  When a Facebook user clicked on the study advertisement, 
they were automatically redirected to the secure study website.  
The Facebook Ads Manager was used to track the total number of impressions 
(each time an advertisement was displayed), the number of times an ad was clicked, the 
average cost-per-click, and the number of people reached (i.e. the number of Facebook 
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users that had an opportunity to view one of the study advertisements). Google Analytics 
software (Mountain View, CA, USA) was used to tabulate the total number of visits, the 
unique visits, the average duration of visits, and the bounce rate (the percentage of 
visitors who visit a website and leave the site without further browsing) of the study 
website. 
Study Procedures 
After providing consent, study participants were asked to self-report their age, 
gender, ZIP code of their home address, race/ethnicity, highest level of education 
attained, attendance at religious services, political preferences, sexual orientation, their 
awareness of HPV, and whether or not they had received the HPV vaccine. Conditional 
upon participants’ responses, follow-up questions regarding the number of shots received, 
the vaccine type (quadrivalent/bivalent), and reason(s) for not having received the 
vaccination, as well as future vaccination intentions were administered. Female 
participants were also asked a series of adaptive questions about past cervical cancer 
screening.  The survey questions regarding HPV vaccination and cancer screening that 
we used in this study were questions used in the five national surveys mentioned above, 
in order to facilitate comparisons between studies.  Participants were not required to 
answer every question and could exit the survey at any time. Computer Internet Protocol 
(IP) addresses were tracked and multiple entries from the same IP address were not 
accepted.  Additionally, survey responses that contained repeated email addresses across 
multiple survey attempts (n=86) or were only partially completed (n=8) were not 
accepted.  The survey was anonymous and was administered using the online survey 
assessment tool SurveyMonkey (SurveyMonkey Inc., Palo Alto, CA, USA).  Eligible 
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respondents who provided informed consent and completed the online survey were 
emailed an electronic gift card in the amount of $20 to Target.com®.   
3.5 Results 
 
Of the 2,079 men and women who were recruited via Facebook and visited the 
study website, 1,003 (48.2%) enrolled in the study and completed the survey.  Targeted 
advertising within Facebook based on geographic and age criteria limited the number of 
ineligible participants (4.4% of all survey attempts) who attempted to access the survey.  
In total, 86 survey attempts (7.5% of all survey attempts) were identified as duplicate 
surveys, indicating that an individual attempted to complete the survey more than once 
(Figure 3.2).  Facebook advertising and recruitment resulted in an average advertising 
cost of $1.36 per completed survey.  In addition, 881 out of the 972 study participants 
(90.6%) who self-reported their ZIP code were located within the recruitment target area 
(i.e. located within a 25-mile radius of downtown Minneapolis, Minnesota) (Figure 3.3).   
A total of 1,003 participants (557 women and 446 men) completed the online 
survey. Characteristics of the study population are presented in Table 3.1. With respect to 
race/ethnicity, the study population was broadly similar to that of 18 to 34 year-olds in 
the greater Minneapolis-St. Paul Metropolitan Area based on U.S. Census data.  
However, due to the age and geographic inclusion and exclusion criteria, the study 
population was more educated than the general population of 18 to 34 year-olds in the 
Minneapolis-St. Paul Metropolitan Area.  In all, 44.2% of respondents (396 of the 896) 
who knew of the HPV vaccine had been vaccinated against HPV (i.e. received ≥1 dose of 
HPV vaccine), with 65.6% of women (351 out of 535) having been vaccinated with ≥1 
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dose of HPV vaccine compared to 12.5% of men (45 out of 361).  Completion of the 
HPV vaccine series (i.e. receipt of all 3 doses) was reported by 74.9% of women (263 out 
of 351) and 22.2% of men (10 out of 45) who had ever received an HPV vaccine. Among 
the 351women who had received ≥1 dose of HPV vaccine, 265 (75.5%) had also received 
at least one Pap smear in their lifetime.   
 Of the 479 unvaccinated men and women, 403 (84.1%) were not interested or 
were unsure about receiving the vaccine in the future.  The main reasons cited were: “not 
necessary or not needed” (45.6%), not sexually active (14.2%), insufficient knowledge 
about HPV or the vaccine (8.9%), concerns about safety or side effects (7.8%), cost of 
the vaccine (6.8%), already infected with HPV (6.1%), in a monogamous relationship 
(3.5%), and too old for the vaccine (1.3%) (Table 3.2).  Eleven men (2.8%) reported that 
the vaccines were not intended for use in men. When participants were allowed to report 
all of the reasons that they would not receive the vaccine in the following 12 months, the 
most frequently cited responses were: “not necessary or needed” (26.8%), provider did 
not recommend the vaccine (13.5%), cost of the vaccine (13.0%), not sexually active 
(10.9%), and concerns about the safety or side effects of the vaccine (9.7%). 
3.6 Discussion 
In this study we found that recruiting a locally representative sample of young 
adults via the Internet to participate in a survey about HPV vaccination was cost-effective 
and efficient.  Approximately half of the 2,079 individuals that clicked on an 
advertisement and visited our study website participated and completed our survey at an 
estimated advertising cost of $1.36 per enrolled participant.  Consistent with other 
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studies, this study found that using the Internet and in particular social media sites such as 
Facebook, can be successful for recruiting and engaging young adults populations for 
health research [102-104].  This method of recruitment is particularly noteworthy given 
declining response rates from traditional recruitment techniques such as random digit 
dialing or mailed surveys [116-118].  In addition to higher participation rates, the targeted 
advertising features embedded within social media websites drastically reduce costs 
associated with identifying and reaching a large pool of eligible participants [111, 113-
114].  The targeted advertising used in this study also allowed us to collect data within an 
accelerated timeline (e.g. pilot testing of a specific intervention) from a specific 
geographic location.   
Notably, the characteristics of our study population were similar to those of the 
source population.  An estimated 90% of Internet users aged 18-29 in the U.S. access 
social media sites (71% accessed Facebook) in 2013, thus this finding is likely 
attributable to the wide reach of social media recruitment [119].  An exception however, 
was that our study population was more educated than the general population in the 
Minneapolis-St. Paul Metropolitan Area which may be due to the large number of 
colleges and universities in this area.  However, it cannot be ruled out that people with 
lower education were less likely to access Facebook and view the advertisements 
although other studies have shown that lower income and less educated participants are 
as likely to participate in Internet-based research studies as those who with higher 
incomes and higher levels of education [114, 120-121].   
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Other limitations include the fact that the survey responses were self-reported by 
persons over the Internet and may be subject to under or over-reporting. However, other 
Internet-based studies have shown increased self-disclosure and reporting with online 
surveys, which may reduce potential response biases (e.g. interviewer bias or social 
desirability) [105, 107]. Additionally, there was no fail proof method to ensure that 
survey responses were unique and there remains a small probability that some 
participants responded more than once. 
In this study we were also able to collect detailed HPV vaccination data, including 
participation in screening (for women) and potential barriers to receiving these services 
among a representative sample of men and women in a defined local geographic area. 
National surveys including the Behavioral Risk Factor Surveillance System, the National 
Health Interview Survey, and the National Immunization Survey-Teen, do not 
simultaneously assess these factors within the same respondents in their populations.  
Additionally, these (and other) national surveys aggregate or suppress responses due to 
participant identification concerns and consequentially local variation and patterns may 
be obscured. However, HPV vaccine policies, availability, costs, financial assistance, and 
education materials vary widely across states or even more defined geographic regions 
[122].  As a result, variation at state and national levels may not reflect the variation in 
HPV vaccine uptake occurring at a local level.   
Of note, the proportion of all adults in this study who had been vaccinated against 
HPV (i.e. received at least one dose of an HPV vaccine) was 44.2% (65.6% for women 
and 12.5% for men). These estimates are much higher than the HPV vaccine coverage 
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estimates from the 2012 National Health Interview Survey (NHIS) for women (34.5%) 
and men (2.3%) aged 19 to 26 [123]. Although the results for women are more similar to 
those obtained from the National Immunization Survey – Teen for girls (53.8%), the 
estimate for men is much lower than the NIS-Teen estimate for boys (20.8%) aged 13 to 
17 who received at least one dose of HPV vaccine in 2012 [15]. Although the differences 
in the observed rates may be partially explained by the sampling frame, response rates, or 
the small number of eligible respondents who received the HPV vaccine question series 
in the national surveys, the estimates of HPV vaccine uptake are noticeably different 
from the current study.   
To our knowledge, this is the first study to estimate local level vaccination uptake 
among young men in the United States.  Understanding the local variation and patterns of 
HPV vaccination of young men could serve to identify areas where HPV infection-related 
health disparities may continue if neglected.  In particular, the online survey also allowed 
us to collect data on sexual orientation which in turn would allow us to understand 
whether men who have sex with men, who are at high risk of HPV-related anal cancer, 
are receiving the vaccine and to also determine whether reductions in the overall risk of 
HPV infection will affect transmission to females [24, 124].  
In conclusion, the results from this study suggest that more detailed and local 
assessments of HPV vaccine uptake are necessary as estimates vary greatly from national 
surveys.  In addition, recruiting young adults via the Internet is efficient, cost-effective, 
and can produce a representative sample of the target population.  Future work is needed 
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to understand the pattern of HPV vaccine uptake at local levels in order to identify areas 
that may be best served by vaccine programs.  
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Table 3.1. Selected study participant characteristics compared to U.S. Census estimates 
for Minneapolis and St. Paul, Minnesota.
a
 
 
 Study Participants  Census Data 
  
Men 
(N=446) 
Women 
(N=557) 
Total 
(N=1,003) 
Mpls./St. Paul 
(%)
 
Mean age (years) 23 23 23 18 to 34
 
Race n (%)     
White 384 (86.3) 457 (82.3) 841 (84.1) 78.1 
Black 17 (3.8) 33 (5.9) 50 (5.0) 8.6 
Asian 30 (6.7) 30 (5.4) 60 (6.0) 7.7 
AI or AN
b
  2 (0.4) 7 (1.3) 9 (0.9) 0.7 
Native Hawaiian or PI
c 
1 (0.2) 3 (0.5) 4 (0.4) 0.03 
Other 11 (2.5) 25 (4.5) 36 (3.6) 4.9 
Ethnicity n (%)     
Hispanic 15 (3.4) 19 (3.4) 34 (3.4) 2.6 
Non-Hispanic 427 (96.6) 533 (96.6) 960  (96.6) 97.4 
Education n (%)     
<High School 2 (0.4) 0 (0.0) 2 (0.2) 1.9 
Some High School 6 (1.3) 8 (1.4) 14 (1.4) 7.9 
High School Graduate 36 (8.1) 36 (6.5) 72 (7.2) 22.1 
Some College/Tech. School 190 (42.7) 209 (37.6) 399 (39.9) 36.7 
College Graduate 167 (37.5) 237 (42.6) 404 (40.4) 24.9 
Graduate School 44 (9.9) 66 (11.9) 110 (11.0) 6.6 
Political Preferences n (%)     
Very Conservative 19 (4.3) 9 (1.6) 28 (2.8) n/a
d
 
Conservative 84 (18.9) 60 (10.8) 144 (14.4) n/a 
Moderate 157 (35.4) 164 (29.5) 321 (32.1) n/a 
Liberal  139 (31.3) 225 (40.5) 364 (36.4) n/a 
Very Liberal 45 (10.1) 97 (17.5) 142 (14.2) n/a 
Religious Attendance n (%)     
More than once per week 23 (5.2) 23 (4.1) 46 (4.6) n/a 
Once per week 55 (12.3) 82 (14.8) 137 (13.7) n/a 
Once or twice per month 56 (12.6) 86 (15.5) 142 (14.2) n/a 
A few times per year 114 (25.6) 118 (21.3) 232 (23.2) n/a 
Seldom 97 (21.7) 103 (18.6) 200 (20.0) n/a 
Never 101 (22.6) 143 (25.8) 244 (24.4) n/a 
Sexual Orientation n (%)     
Heterosexual 398 (91.5) 499 (91.9) 897 (91.7) n/a 
Homosexual, gay, or lesbian 33 (7.6) 11 (2.0) 44 (4.5) n/a 
Bisexual 4 (0.9) 33 (6.1) 37 (3.8) n/a 
aData are 5-year estimates for 18 to 34 year-olds in the Minneapolis-St. Paul Metropolitan Area as described in the 
2006-2010 American Community Survey of the United States Census Bureau. 
bAmerican Indian or Alaska native 
cPacific Islander 
dnot available 
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Table 3.2. Selected survey responses regarding vaccination against human 
papillomavirus.  
 
 Survey Question Men  
(N=446) 
Women  
(N=557) 
Total  
(N=1003) 
 n (%) n (%) n (%) 
Ever heard of HPV
a
    
Yes 409 (93.0) 536 (96.8) 945 (95.1) 
No 31 (7.0) 18 (3.2) 49 (4.9) 
Ever heard of HPV vaccine     
Yes 361 (82.4) 535 (96.6) 896 (90.3) 
No 77 (17.6) 19 (3.4) 96 (9.7) 
Ever had HPV vaccine     
Yes 45 (13.0) 351 (66.5) 396 (45.3) 
No  302 (87.0) 177 (33.5) 479 (54.7) 
Number of HPV shots     
1 shot 11 (24.4) 31 (8.8) 42 (10.6) 
2 shots 14 (3.9) 38 (10.8) 52 (13.1) 
3 shots (complete vaccine series) 10 (22.2) 263 (74.9) 273 (68.9) 
 Don’t know 10 (22.2) 19 (5.4) 29 (7.3) 
Vaccine receipt
b
 (next 12 mo)     
Very likely 7 (2.3) 13 (7.3) 20 (4.2) 
Somewhat likely 26 (8.6) 30 (16.9) 56 (11.7) 
Not too likely 75 (24.8) 47 (26.6) 122 (25.5) 
Not likely at all 173 (57.3) 84 (47.5) 257 (53.7) 
Not sure/don’t know 21 (7.0) 3 (1.7) 24 (5.0) 
Reason no HPV vaccine
b
 (next 12 mo)    
Not needed or necessary 140 (52.4) 40 (31.3) 180 (45.6) 
Not sexually active 33 (12.4) 23 (18.0) 56 (14.2) 
Knowledge
d
 25 (9.4) 10 (7.8) 35 (8.9) 
Safety concerns/side effects 9 (3.4) 22 (17.2) 31 (7.8) 
Costs 13 (4.9) 14 (10.9) 27 (6.8) 
Already have HPV 19 (7.1) 5 (3.9) 24 (6.1) 
Monogamous 8 (3.0) 6 (4.7) 14 (3.5) 
Other
e
 6 (2.2) 6 (4.7) 12 (3.0) 
Not for men 11 (4.1) 0 (0.0) 11 (2.8) 
Too old 3 (1.1) 2 (1.6) 5 (1.3) 
a
Human papillomavirus 
b
Responses presented are for the 479 individuals who reported not having been vaccinated against HPV. 
cThis question was asked among participants who responded “not too likely,” “not likely at all,” or “not 
sure/don’t know” when asked if they would receive the HPV vaccine in the next 12 months. 
dDon’t know about HPV or HPV vaccine 
eResponses included “fear of needles,” “too busy/no time,” “don’t use vaccines,” or “already sexually 
active.”  
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Figure 3.1.  Examples of Facebook advertisements. 
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Figure 3.2. Manuscript 2 recruitment summary flowchart. 
  
 
 
Facebook advertisement impressions 
(n = 3,254,666) 
Total study website visits 
(n = 2,440) 
Unique visitors 
(n = 2,079) 
Survey attempts 
(n = 1,147) 
Completed surveys 
(n = 1,003) 
Ineligible surveys 
(n = 144) 
 Duplicate survey response (n = 86) 
 Not a Minnesota resident (n = 22) 
 Did not meet age requirements (n = 
28) 
 Incomplete survey attempt (n = 8) 
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Figure 3.3. Map of the recruitment target area and the number of completed surveys by 
ZIP code. 
  
 
The recruitment target area for this study was a 25-mile radius from downtown Minneapolis, Minnesota (represented 
by the orange circle). Of the 972 participants that reported their ZIP code, 881 (90.6%) lived within the recruitment 
study area. MSP indicates Minneapolis-St. Paul. 
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Chapter 4. Manuscript 2: Geographic Variation in Human Papillomavirus Vaccine 
Uptake at the ZIP Code Level in Minnesota.   
 
4.1 Overview of Manuscript 2 
 
 The objective of Manuscript 2 was to describe and evaluate the distribution of 
HPV vaccination practices by ZIP code in the Twin Cities Metropolitan Area.  This study 
aggregated participant responses from the SMASH Study (described in Manuscript 1) by 
ZIP code in order to estimate and map the distribution of HPV vaccination uptake in the 
Twin Cities Metropolitan Area (Aim 3). Understanding the effects of geographic 
variation and the impact of residential patterns on HPV vaccine receipt will more fully 
identify where disparities exist and where vaccination strategies may yield the most 
benefit.  
 Spatial statistics permit the analysis of distributions, patterns, processes, and 
relationships across space and time. While there are some similarities between spatial and 
non-spatial (traditional) statistics in terms of concepts and objectives, spatial statistics are 
unique in that they were developed specifically for use with geographically referenced 
data. Unlike traditional non-spatial statistical methods, spatial statistics explicitly 
incorporate space (proximity, area, connectivity, and/or other spatial relationships). For 
this manuscript, spatial logistic models were employed to determine the spatial pattern of 
HPV vaccination by ZIP code in the Twin Cities Metropolitan Area.  
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4.2 Summary 
 
Background: Research describing the geographic variability in human 
papillomavirus (HPV) vaccination uptake at the state or county level is limited, has relied 
on data collected from large national surveillance programs and has, to date, not 
accounted for spatial autocorrelation (i.e. the degree to which data values are related 
based on their distance from one another).  A concern with assuming national data can be 
used to infer local variation in HPV vaccine uptake is that use of such data may mask 
significant variability and potential disparities at the local level.   
Objective: To determine if there is geographic variation, and if so, to examine the 
pattern in HPV vaccine uptake using ZIP code level data, and to identify predictors of 
vaccination while accounting for spatial autocorrelation.   
Methods: Data on HPV vaccination at the ZIP code level were collected for 760 
individuals nested within 99 ZIP codes surrounding the downtown area of Minneapolis, 
Minnesota. Proper conditional autoregressive (CAR) models, which account for spatial 
dependence, were used to identify predictors associated with receipt of HPV vaccination. 
Results: In all, 46.2% of participants had received at least one dose of HPV 
vaccine (67.7% of women reported having been vaccinated compared to 13.0% of men).  
HPV vaccination was found to exhibit strong spatial dependence ( ). 
Accounting for spatial dependence, older age (OR = 0.76, 95% CI = 0.71-0.82) and male 
gender (OR=0.03, 95% CI = 0.02-0.05) were negatively associated with vaccination, 
while moderate (OR = 3.24, 95% CI = 1.62-6.49) and liberal political preferences (OR = 
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5.32, 95% CI = 2.68-10.58) were found to be significant positive predictors of HPV 
vaccination.  
Conclusions: This study highlights the need to account for spatial dependence 
when looking at geographic variation in HPV vaccination. This study also underscores 
the need for more detailed data collected at the local level as ZIP code level patterns of 
HPV vaccine receipt were found to differ significantly from aggregated state and national 
patterns. 
4.3 Introduction 
Human papillomavirus (HPV) is the most common sexually transmitted infection 
in the U.S. [1], and is the necessary cause of cervical cancer [2].  HPV infections are also 
associated with other cancers (e.g. anogenital and oropharyngeal) as well as genital warts 
[3-4].  Since mid-2006, the Advisory Committee on Immunization Practices (ACIP) has 
recommended routine vaccination of adolescent girls aged 11 or 12 years with the three-
dose HPV vaccine series [13].  In October 2011, the ACIP extended their 
recommendation of the quadrivalent vaccine to include boys aged 11 or 12 years old [12, 
14]. The ACIP also recommends catch-up vaccination for those aged 13 to 26 years. 
However, HPV vaccination uptake has been far lower than expected, with only 53.8% of 
girls and 20.8% of boys aged 13-17 years and 34.5% of women and 2.3% of men aged 
19-26 years receiving at least one dose of the vaccine as of 2012 [123, 125].  Despite 
lower than anticipated vaccine uptake, recently published HPV vaccine serosurvey results 
show significant reductions in HPV prevalence, and reductions in HPV-associated cancer 
incidence of approximately 70% are predicted in the coming decades [72-74, 126-127].    
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Initiation of the HPV vaccine (i.e. receiving at least one dose) has been shown to 
be higher among minority adolescent girls; however, completion of the three-dose series 
is substantially lower among blacks and Hispanics compared to whites [95]. Although 
male vaccination data are very limited, racial and income differences have also been 
observed among adolescent boys [96].  Disparities in receipt of the HPV vaccine have 
also been found to be associated with access to healthcare, clinical provider 
characteristics, and parental perceptions of the HPV vaccine [96, 99, 128-132].   
Research on the geographic variability of HPV vaccination is limited, and has 
relied on data collected from large national surveillance programs to estimate uptake at 
the state or county levels [100-101, 133].  These national data on geographic variation in 
HPV uptake may mask a considerable amount of variability at more localized levels.  
Further, a major limitation of these geographic studies is that they do not account for the 
areal units on which data are recorded, commonly referred to as the spatial structure of 
the data.  Data collected in this manner typically exhibit spatial dependence (also referred 
to as spatial autocorrelation), with observations from areal units close together tending to 
have similar values [134].  Although a proportion of spatial dependence may be modeled 
by including known covariate risk factors (i.e. age, race, sex) in a traditional regression 
model, it is common for spatial structure to not be accounted for and to remain in the 
residuals even after accounting for these covariate effects (i.e. to be spatially confounded) 
[134].  For example, one study noted several individual factors that were predictive of 
receipt of HPV vaccination, including geographic region of residence, however they did 
not fully account for spatial dependence as they used a categorical variable to account for 
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geographic differences in uptake [135].  Another study that analyzed geographic variation 
in HPV vaccine uptake used a weighting scheme to account for the complex selection of 
study participants, yet ignored accounting for the spatial dependence between geographic 
regions [101].  Thus, these studies inherently assume that factors associated with HPV 
vaccine uptake are homogeneous across areal units (i.e. states or counties). To date, the 
intra-county geographical variation of HPV vaccination has not been examined while 
accounting for spatial dependence.  Documenting geographic variation in vaccine 
disparities at local levels may help to identify specific areas with the largest disparities in 
HPV vaccine uptake (after accounting for spatial dependence) thereby informing 
outreach efforts, and may also provide new hypotheses regarding the underlying 
determinants of geographic patterns in uptake.  
The objective of this study was to use HPV vaccination data measured at the ZIP 
code level to identify geographic variation in vaccine uptake, and to identify predictors of 
receipt of HPV vaccination while accounting for spatial dependence.   
4.4 Methods 
Data 
This study utilized data collected on 1,003 participants from the Survey of 
Minnesotans About Screening and HPV (SMASH) study, which is a cross-sectional study 
of English-speaking men and women aged 18-30 years from the Twin Cities 
Metropolitan Area of Minnesota (Manuscript 1).  Briefly, from November 2012 to 
January 2013, targeted advertisements were displayed on the social networking site 
Facebook™ to men and women who met the study eligibility criteria (as specified in their 
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user profiles).  Men and women who clicked on a study advertisement were redirected to 
the secured SMASH study website and invited to participate in an online survey.  After 
providing consent, participants were asked to answer questions regarding HPV 
vaccination, cancer screening, and barriers/intentions regarding receipt of either.  
The response to the question “Have you ever received an HPV vaccine?” was 
used as the current study’s outcome variable for HPV vaccination status.  Individuals 
(n=128) who responded don’t know, refused, or who did not respond to this question 
were excluded from the study. Similarly, individuals who did not report their ZIP code 
(n=3), or who reported a ZIP code outside of the predetermined 25-mile radius of 
downtown Minneapolis, Minnesota (n=112) were excluded from the study in order to 
focus on this diverse metropolitan population. The resulting study sample consisted of 
760 (75.8% of total enrolled) men and women nested within 99 ZIP codes.   
Spatial Data Analysis  
Spatially dependent data violate the independence assumption required for 
generalized linear models.  As such, ignoring the dependence of spatial data can lead to 
underestimation of standard errors, resulting in overly narrow confidence interval 
estimates and, consequently, incorrect statistical inference [136].  To account for residual 
dependence it is standard practice to augment the linear predictor with a spatial random 
effect, as part of a Bayesian hierarchical model [137]. These random effects typically 
take the form of a conditional autoregression (CAR), which introduces spatial 
dependence through the adjacency structure of areal units [137].  CAR models are 
generally applied in a Bayesian setting, where inference is based on Markov-chain Monte 
Carlo (MCMC) simulation [138]. 
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To accommodate the potential spatial dependence of HPV vaccination, we 
implemented a spatial logistic regression model using ZIP code as the areal unit of 
analysis.  Assume Yi is the number of respondents who were vaccinated against HPV out 
of the total Ni sampled in each ZIP code j.  The outcome can be modeled as a binomial 
response Yij ~ bin(pij, Nij) such that pij is the true vaccine uptake proportion of individual i 
within a selected ZIP code j. The proportions were smoothed using the following model, 
                                       logit(pij) = α + βXij + sj               (1) 
where α is an intercept, which is interpreted as an overall log-odds coverage for all areas; 
β are the effects of the covariates Xij in the model; and the sj are spatially dependent 
random effects, such that neighboring areas have a similar vaccine uptake proportion. 
The parameter ρ (termed rho) is a spatial autocorrelation parameter that is estimated as 
part of the spatially dependent random effect sj
 
[137].  Rho describes the strength of 
spatial dependency, with 0 corresponding to spatial independence, while 1 corresponds to 
strong dependence [139-140].  Including information from neighboring ZIP codes to 
further inform the estimate for each ZIP code, even when the sample size is small, has 
been demonstrated to create sufficient statistical power to generate unbiased estimates 
[141].  This is achieved by assuming a proper CAR prior, defined as N(sj|k, 1/τsmj), where 
si|j is the pooled mean of area j, based on the adjacent areas k, and mj are the number of 
ZIP codes neighboring j, while τs is the precision that controls the amount of smoothing 
[142-143].  By convention, the intercept and regression coefficients were assigned a 
conservative normal prior with a mean of 0 and a standard deviation of 0.00001.  
Estimation of the model parameters was carried out with MCMC simulation techniques 
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that were implemented in R version 3.0.1 (R Development Core Team, 2014).  Model 
convergence was monitored using a Monte Carlo standard error threshold of 0.1 [144].  
For this analysis, a total of 1,000,000 posterior samples were generated.  
 All statistical models were adjusted for a priori factors potentially associated with 
HPV vaccine uptake, including sex, age (mean-centered), race (white, African American, 
American Indian/Alaska native, Asian, or other), ethnicity (Hispanic vs. non-Hispanic), 
educational attainment (some high school, high school graduate, some college or 
technical school, college graduate, or graduate school), sexual orientation (heterosexual, 
homosexual/gay/lesbian, or bisexual), and political views (very conservative, 
conservative, moderate, liberal, or very liberal).  Initially, the model was fit maintaining 
all the variables.  The final model retained all covariates that were statistically significant. 
Results for regression coefficients are presented, along with odds ratios and the 
associated 95% credible intervals. The random effect terms can be interpreted as the 
effect of ZIP code on HPV vaccination uptake for each individual.  
4.5 Results 
Characteristics of the study sample are presented in Table 4.1.  In all, 46.2% of 
participants had received at least one dose of HPV vaccine, with 67.7% of women 
reporting having been vaccinated compared to 13.0% of men.  Of those who initiated the 
vaccine series, 71.1% completed the entire three-dose series (79.6% of women and 26.3% 
of men). Participants who had been vaccinated against HPV (i.e. received ≥1 dose of the 
vaccine) were younger (of those over age 25, 30.1% were vaccinated compared to 69.9% 
who were not).  Vaccine receipt was lower among those who identified themselves as 
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politically “conservative” or “very conservative” as opposed to politically “liberal” 
(24.6% compared to 53.3%). 
 HPV vaccination was found to exhibit strong spatial dependence ( ).  
The average spatially dependent random effect estimate for each ZIP code is shown in 
Figure 4.1.  The magnitude of these effects is represented with varying shades of blue, 
with larger effects shown with darker shades of blue.  The CAR model also successfully 
converged, as the maximum Monte Carlo standard error was 0.035 (which was below our 
threshold of 0.1), indicating that a sufficient number of posterior samples were generated 
for the estimates to stabilize.  Estimates for the best-fitting CAR model are shown in 
Tables 4.2 and 4.3.  After accounting for spatial dependence using the CAR model, age, 
sex, and political preferences remained significant predictors of HPV vaccine receipt.  
Specifically, older age (OR = 0.77 per year, 95% CI = 0.72-0.83) and being male 
(OR=0.03, 95% CI = 0.02-0.06) were associated with a decreased odds of HPV vaccine 
receipt.  Moderate and liberal political preferences (referent to very conservative and 
conservative preferences) were associated with an increased odds of HPV vaccine receipt 
(moderate OR = 3.24, 95% CI = 1.62-6.49; liberal OR = 5.32, 95% CI = 2.68-10.58).  For 
comparison, regression coefficients, odds ratios, and corresponding 95% confidence 
intervals from a traditional logistic regression model that does not account for spatial 
dependence were also estimated and are also presented in Tables 4.2 and 4.3.  Compared 
to the traditional logistic model, estimates from the CAR model were greater in 
magnitude for all covariates. Of note, in the traditional logistic regression model, 
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education and race were statistically significant factors but were not significant in the 
CAR model.  
4.6 Discussion 
In this study, HPV vaccination was found to exhibit strong spatial dependence, 
indicating that spatial statistical models are needed to accurately identify and estimate 
factors associated with HPV vaccine uptake.  As a result, ignoring this spatial 
dependence can lead to biased point estimates and overly narrow credible intervals. 
Consistent with other studies, younger age, female gender, and political views were 
found to be significant predictors of HPV vaccination (after accounting for spatial 
dependence) [97-99, 135]. The associations of age and sex with HPV vaccine receipt can 
be attributed, in part, to the evolving ACIP recommendations, as they were first 
recommended for use in young girls and were later expanded to include young boys.  
Conservative political views have also been found to be associated with decreased 
knowledge of HPV, lower perceived risk of infection with HPV, and stronger views 
against premarital sex [145].   
However, contrary to other studies that have not accounted for spatial 
dependence, this study found that education and race were not significant predictors of 
HPV vaccination [97-99, 135, 146-147].  Racial disparities (and other disparities) have 
been shown to be pronounced in some areas, while less evident (or absent) in other areas 
[148-150]. Although the existence of these disparities is well documented, the overall 
average effects can mask variation across local areas [151].  For example, in a traditional 
regression analysis when minority girls live in regions with systematically different rates 
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of HPV vaccine uptake, and the region is not controlled for, one could erroneously 
conclude that racial “disparities” exist when in fact the where people live is the 
significant predictor of vaccination. Thus, ignoring geography (i.e. the spatial dependence 
of the data) may lead to incorrect inference.  Previous studies that have attempted to 
describe geographic variation in HPV vaccine uptake have either ignored spatial 
dependence completely or have not correctly accounted for it using spatial statistical 
models. Therefore, these studies have concluded that covariates such as education and 
race were significant predictors of receipt of the HPV vaccine when these conclusions are 
likely to be biased because they do not account for spatial dependence.  Using models 
that can account for spatial dependence is requisite in order to identify independent 
predictors that are truly associated with HPV vaccination (as opposed to spatially 
confounded covariates), particularly when analyzing data from varying geographic 
locations.      
This study demonstrates the geographical variation of HPV vaccination within 
ZIP codes in the Twin Cities Metropolitan Area (at a scale that is smaller than that which 
is currently available through national surveys) and emphasizes the advantage of 
estimating vaccine uptake at local levels (i.e. intra-state or intra-county).  Previous 
studies have demonstrated that HPV vaccination uptake varies across large geographical 
regions and within state boundaries [100-101, 133, 135].  HPV vaccine policies, 
availability, costs, financial assistance, and education materials have been shown to vary 
widely across states or within more defined geographic regions [122].  As a result, 
variation at state and national levels may not reflect the variation in HPV vaccine uptake 
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occurring at a local level.  A finer level of analysis was not possible in these studies 
because of the sparseness of data at the county and ZIP code levels, which is in part 
attributable to national surveys aggregating or suppressing responses due to participant 
identification concerns.  One strength of this study is that ZIP code level data were 
available to conduct a more detailed spatial analysis. Specifically, this study demonstrates 
that HPV vaccine uptake does indeed vary widely within counties at the ZIP code level. 
This study also identifies significant predictors of vaccination after accounting for spatial 
autocorrelation, and isolates ZIP codes where targeted efforts are needed and may 
eventually have the greatest impact on reducing the HPV-associated disease burden in the 
Twin Cities.   
There are several limitations to this study. First, all study measures were self-
reported by persons over the Internet and may be subject to under or over-reporting.  
However, recent studies have shown recall of HPV vaccination status to be accurate 
[152].  In addition, Internet-based studies have shown increased self-disclosure and 
reporting with online surveys, which may reduce potential response biases (e.g. 
interviewer bias or social desirability) [105, 107].  Second, the spatial analysis was 
conducted at the ZIP code level and assumes a common ZIP code level effect, so within-
ZIP code differences may be masked.  However, to our knowledge, this study has 
examined HPV vaccination at the smallest unit thus far.  In addition, this study utilizes 
cross-sectional data and temporal effects cannot be established. 
In conclusion, the results from this study demonstrate that more detailed and local 
assessments of HPV vaccine uptake that account for spatial dependence are necessary as 
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ZIP code level patterns differ significantly from aggregated state and national patterns.  
Future work is needed to further pinpoint areas with the greatest disparities and how to 
then access these populations to improve vaccine uptake. 
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Table 4.1. Characteristics of study participants by HPV vaccination status.  
  Vaccinated Not Vaccinated Total 
  (n=351) (n=409) (n=760) 
  N % N % N % 
Age, in years             
18-20 86 51.8 80 48.2 166 21.8 
21-25 209 51.2 199 48.8 408 53.7 
26-30 56 30.1 130 69.9 186 24.5 
Gender 
      
Female 312 67.7 149 32.3 461 60.7 
Male 39 13.0 260 87.0 299 39.3 
Race 
      
White 298 46.3 346 53.7 644 84.7 
Black 22 61.1 14 38.9 36 4.7 
Am. Indian/AL native 4 50.0 4 50.0 8 1.1 
Asian 15 34.1 29 65.9 44 5.8 
Other 12 42.9 16 57.1 28 3.7 
Hispanic/Latino 
      
Yes 13 48.1 14 51.9 27 3.6 
No 336 46.2 391 53.8 727 96.4 
Education 
      
Some High School 4 1.1 3 0.7 7 0.9 
High School Graduate 19 5.4 25 6.1 44 5.8 
Some College or Tech. School 135 38.5 151 36.9 286 37.6 
College Graduate 152 43.3 175 42.8 327 43.0 
Graduate School 41 11.7 55 13.4 96 12.6 
Sexual Orientation 
      
Heterosexual 311 45.7 370 54.3 681 89.7 
Homosexual, gay, or lesbian 12 36.4 21 63.6 33 4.3 
Bisexual 21 65.6 11 34.4 32 4.2 
Don’t know/Refused 7 53.8 6 46.2 13 1.7 
Political Views 
      
Very Conservative 1 4.5 21 95.5 22 2.9 
Conservative 28 29.2 68 70.8 96 12.6 
Moderate 103 44.6 128 55.4 231 30.4 
Liberal 154 52.0 142 48.0 296 38.9 
Very Liberal 65 56.5 50 43.5 115 15.1 
 HPV indicates human papillomavirus 
a
Other indicates Native Hawaiian or Pacific Islander, more than one race, or a 
response of “other.” 
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Table 4.2. Regression estimates for factors associated with HPV vaccination from 
traditional logistic regression and spatial CAR models.  
 
  Traditional Logistic Model Spatial CAR Model 
  Estimate Standard Error Estimate Standard Error 
Intercept -0.132 0.253 -0.702 0.329 
Age
a
 -0.139 0.029 -0.273 0.036 
Male
b
 -2.629 0.205 -3.560 0.239 
Political Views
c
         
Moderate 0.850 0.295 1.176 0.355 
Liberal  1.036 0.285 1.672 0.351 
Very Liberal 1.233 0.336 1.755 0.399 
HPV indicates human papillomavirus
 
a
Age is centered at 23.24 years old 
b
Referent to females 
cReferent to combined responses of “very conservative” and “conservative” 
 
 
 
 
Table 4.3. Odds ratio estimates for factors associated with HPV vaccination from 
traditional logistic regression and spatial CAR models. 
 
  Traditional Logistic Model Spatial CAR Model 
  Odds Ratio 95% CIa Odds Ratio 95% CIb 
Agec 0.87 (0.82-0.92) 0.76 (0.71-0.82) 
Sex         
Female 1.0 (referent) 1.0 (referent) 
Male 0.07 (0.05-0.11) 0.03 (0.02-0.05) 
Political Views         
Conservatived 1.0 (referent) 1.0 (referent) 
Moderate 2.34 (1.31-4.17) 3.24 (1.62-6.49) 
Liberal  2.82 (1.61-4.92) 5.32 (2.68-10.58) 
Very Liberal  3.43 (1.78-6.63) 5.78 (2.64-12.65) 
HPV indicates human papillomavirus
  
a
95% Confidence Interval 
b
95% Credible Interval 
c
Age is centered at 23.24 years old 
dReferent group consists of “conservative” and “very conservative” responses 
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Figure 4.1. Map of spatially dependent random effect estimates from the final spatial 
CAR model. 
 
The average spatially dependent random effect estimate was mapped for each ZIP code in the study area.  
The magnitude of these effects is represented with varying shades of blue, with larger effects shown with 
darker shades of blue.  
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Chapter 5. Manuscript 3: Human papillomavirus infection in women who submit 
self-collected vaginal swabs after internet recruitment 
 
5.1 Overview of Manuscript 3 
The objective of Manuscript 3 was to determine the feasibility of obtaining self-
collected HPV test-based screening from women recruited via the Internet.  This project 
aimed to determine whether women who were recruited via the Internet would provide 
self-collected biological samples for cervical cancer screening (HPV DNA testing) and if 
this screening method was an acceptable alternative to clinic-based screening (Aim 4). 
This at-home self-collection approach may also reduce health disparities by offering an 
approach that might be more acceptable to women from different backgrounds, including 
those who may refuse screening due to cultural issues, inconvenience, or cost.  
5.2 Summary 
Background: Submission of vaginal samples collected at home could remove 
barriers that women face in getting screened for cervical cancer. 
Methods: From December 2013 to January 2014, women aged 21-30 years were 
recruited online to participate in either (1) self-collected testing for human papillomavirus 
infection (HPV) and an online survey, or (2) an online survey regarding their perceptions 
of self-collected testing for HPV infection. Demographics, risk factors, testing 
perceptions, and satisfaction with self-collected testing were assessed with online 
questionnaires.  Women who performed self-collection were sent a home sampling kit by 
U.S. mail, which was returned via U.S. mail for HPV testing.   
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Results: A total of 197 women were enrolled, with 130 completing the online 
survey and 67 participating in self-collection. Of the 67 women who were sent kits, 62 
(92.5%) were returned for testing. Sixty kits contained a sample sufficient for testing.  
The overall prevalence of HPV infection was 17.8%, yet 6 women (9.7%) were infected 
with >1 type of HPV.  Women who self-collected a sample reported more favorable 
attributes of self-collection compared to women who only participated in the online 
survey, including ease of sampling (87.1% vs. 18.9%), no pain during sampling (72.6% 
vs. 5.6%), and lack of embarrassment (67.7% vs. 12.9%).  
Conclusions: A high prevalence of HPV infection was demonstrated among 
women recruited via the internet. Online recruitment and at home screening methods 
have the potential to engage women in screening by offering an approach that might be 
more acceptable to women of different backgrounds.   
5.3 Introduction 
 Persistent infection with human papillomavirus (HPV) is the major cause for 
cervical cancer and genital warts [11, 153].  Genital HPV is sexually transmitted, and 
infections are very common, with the prevalence of HPV infections peaking between 
ages 18 and 30 [60-61, 154].  Most women in the world will be infected with genital 
HPV(s) at some time in their lives, with a lifetime risk of infection between 50-80% [49]. 
Most infections will clear spontaneously, however an estimated 10-20% of infections can 
persist, progress to precancerous lesions and eventually invasive cancer of the cervix if 
left untreated [2, 155-156].   
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 HPV DNA testing is currently recommended in combination with cervical 
cytology for cervical cancer screening in women 30 years and older[157] due to its high 
sensitivity for detecting cervical precursor lesions [158].  Recently, the Food and Drug 
Administration approved the use of primary stand-alone type specific HPV DNA testing 
in women aged 25 years or older [159].  Currently, HPV DNA testing is typically 
performed in a clinic by a clinician who collects a cervical sample during a pelvic exam 
[160].  However, HPV DNA has the potential, unlike cervical cytology, to be self-
collected. Studies of self-collected vaginal samples for HPV testing, which can be 
collected in non-clinical settings, have shown a high concordance between samples 
collected by patients and those obtained by clinicians [93, 161-164].  In addition, women 
have generally responded positively to collecting their own samples [94, 165-167].  
However, these studies have been conducted in clinical settings in which clinic staff has 
usually provided instructions for self-collection.  It is unclear whether HPV tests can be 
collected independently of a clinic setting and clinician instructions.  
 One potentially promising method for accessing women who are eligible for 
cervical cancer screening is internet-based recruitment via social networking sites such as 
Facebook™.  Social media advertising permits the advertiser to target messages to 
specific groups based on their characteristics (i.e. age or race) and geographic location.  
One survey conducted in the U.S. in 2013 estimated that 90% of young adults aged 18-29 
have a Facebook account, with 71% identifying Facebook as their primary social media 
site [119].  To date, no HPV self-collection study has used online recruitment to recruit 
women to self-collect a sample for HPV testing [89, 167-170].  The objective of this 
  56 
study was to determine the feasibility of initiating at-home HPV self-collected testing 
among women aged 21 to 30 in Minnesota who had been recruited using advertisements 
on the social networking site Facebook. 
5.4 Methods  
Study Participants 
This study is based on the Survey of Minnesotans About Screening and HPV 
(SMASH) study, which is a cross-sectional study of English-speaking men and women 
aged 18-30 years from the Twin Cities Metropolitan Area of Minnesota (Manuscript 1). 
Briefly, we utilized targeted advertising on Facebook from November 2012 to January 
2013 to promote our study to men and women who met the study eligibility criteria (as 
specified in their user profiles).  Men and women who clicked on a study advertisement 
were redirected to the secured SMASH study website, where they were invited to 
participate in an online survey.  After providing consent, participants were asked to 
answer questions regarding HPV vaccination, cancer screening, and barriers/intentions of 
receiving these health services.  Participants were also asked if they would like to be 
contacted for future health studies about HPV.  In total, 369 (out of 557) female 
participants responded in the SMASH survey that they would be willing to participate in 
future HPV studies. To be eligible for the present study, participants had to be female, 
aged 21 to 30 years, not pregnant, not immunocompromised, could not have received 
treatments in the preceding 2 years for cervical lesions, and must have resided in the 
greater Twin Cities Metropolitan Area.  Of the 369 women who expressed their interest 
in future HPV studies, 300 met the eligibility requirements for this study.  This study was 
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approved by the University of Minnesota Institutional Review Board, Minneapolis, 
Minnesota. 
Participant Selection and Assignment  
 Participants were assigned to either (1) self-collect a sample and complete an 
online survey regarding their experiences or (2) complete an online acceptability survey 
regarding their perceptions of self-collected testing for HPV infection (see Figure 1). A 
random sample of eligible women (n=123) were invited to participate in at-home self-
collected HPV DNA testing and to complete an online survey. The remaining women 
who were not invited to self-collection (n=177) and those women who were invited to 
participate in self-collection but did not enroll in self-collection (n=56) were invited to 
complete the online acceptability survey.  Potential participants were contacted up to 
three times by email and invited to participate. Each email contained a secured link to the 
study website where participants could learn more about the study and choose to 
participate. Women that responded to the email invitations and provided informed 
consent were enrolled in the study.     
Self-Collection Arm  
 Women who were invited to participate in the self-collection arm of the study 
were asked to 1) provide a personal mailing address, 2) to self-collect a vaginal sample at 
home for HPV DNA testing, 3) to return the sample via mail, and 4) to complete an 
acceptability questionnaire after self-collection (this will be referred to as the post-
collection survey).  Women that completed the sampling, returned the sample, and 
completed the post-collection survey were issued a $50 electronic gift card as 
compensation.  
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Self-Collection Kit 
 Self-collection kits were mailed to all participants in the self-collection arm of the 
study. The self-collection kit contained illustrated instructions for collecting a vaginal 
sample, disposable examination gloves, two Q-tip swabs for sampling, a plastic vial to 
protect the samples during shipping, and a pre-paid envelope for return mailing.  Women 
were instructed to wash their hands, gently insert the Q-tip into their vagina as far as they 
could without hurting (as they would a tampon), rotate the Q-tip three times while inside 
their vagina, remove the Q-tip, and insert the Q-tip directly into a plastic vial for 
transport.  Once the samples were collected, participants were asked to indicate the date 
the sample was collected and to package the samples for safe shipping. They were then 
instructed to place the samples in a mailbox (or deliver to a nearby U.S. post office) on 
the same day that they collected the samples.  
Post Self-Collection Survey 
 Women who completed self-collection were asked to complete a questionnaire 
about their experiences with the self-collection process.  Specifically, participants were 
asked to report any pain or discomfort they experienced while using the kit (using 10-
point Likert scales), what they liked and disliked about the self-collection process, 
whether they preferred self-collected screening or clinician-based screening, how 
comfortable they would feel if they were to receive a negative HPV test result from this 
kind of testing, and their preferred method of notification if they were to be informed of a 
positive HPV test result.  The survey was administered using the online survey 
assessment tool SurveyMonkey (SurveyMonkey Inc., Palo Alto, CA, USA).   
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Acceptability Survey Arm 
 Women who were assigned to the online acceptability survey arm of the study 
were invited to complete a short online survey (administered using Survey Monkey) 
immediately after providing informed consent. The survey contained questions regarding 
preferences, opinions, and perceptions of self-collecting a vaginal sample for cervical 
cancer screening. The questions were the same as the post-collection survey questions, 
except that they asked participants how they would feel under the hypothetical scenario 
of self-collecting a sample without actually having participated in self-collected 
screening.  Participants who completed this survey received a $5 electronic gift card as 
compensation.  
Measurements 
 In order to determine the feasibility of recruiting women via the Internet to 
participate in HPV DNA testing, the mean time for a subject to return a kit, the number of 
kits that were successfully completed, and the overall response rate of women were 
tabulated. Mean response time was measured as the number of days that elapsed between 
sending the kit until the sample was received at the study laboratory.  The overall 
response rate was calculated by counting the number of women who responded to the 
study email invitations divided by those who were contacted and invited to participate.  
 The number of successful kits was measured as the number of returned samples 
that contained a sufficient sample (yes/no) to conduct HPV DNA testing. Each sample 
was tested for the presence of HPV DNA using PCR [171]. Samples that were positive 
for HPV were genotyped using restriction fragment polymorphism analysis.  This method 
discriminates between infections with single, multiple and novel HPV types. Samples 
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that did not contain enough cellular matter for HPV DNA testing were classified as 
insufficient for testing.  
5.5 Results 
Self-Collection Arm  
 Of 123 women who were invited to participate in self-collection, 67 (54.5%) 
agreed to provide a self-collected vaginal sample for HPV testing.  Of the 67 kits that 
were mailed to these women, 62 (92.5%) were returned for HPV testing.  Sixty kits 
contained a sample sufficient for testing; 2 kits did not.  Of the samples that were 
sufficient for testing, 17.8% (11 out of 60) were positive for at least one type of HPV.  
Six samples (9.7%) were positive for >1 HPV type.  The overall mean time for a subject 
to return a kit was 13.1 days (SD = 13.6).  Participant characteristics are presented in 
Table 5.1.  Women who enrolled in the study were also similar to those who did not 
enroll in terms of age, race, education, and HPV vaccination status, irrespective of their 
assignment to self-collection or to the acceptability survey (see Tables 5.2 and 5.3). 
 Women who self-collected a vaginal sample at home reported that they liked the 
self-collection process because it was “easy” (87.1%), “not painful” (72.6%), and 
“private” (85.5%). Women reported that their primary dislike of the self-collection 
process was that they were “not sure they did it right” (56.5%), or because “it was 
painful” (8.1%). In all, two women (3.2%) reported that they did not like self-collecting a 
sample at home.  After performing a self-collected HPV test, 1 out of 4 women preferred 
this method to a pelvic exam and Pap smear by a clinician, with 1 in 3 women preferring 
self-collection in combination with a pelvic exam and Pap smear by a clinician. Under 
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the hypothetical scenario of receiving a negative HPV test result after submitting a self-
collected sample, 25.8% of women reported that they would feel comfortable not seeing a 
physician, compared to 30.6% of women who would not feel comfortable and 40.3% who 
might feel comfortable not seeing a physician (see Table 5.4).          
Acceptability Survey Arm  
Of the 233 women invited to participate in the online acceptability survey, 130 
(55.8%) completed the survey.  These women reported that they would like the self-
collection process because it would be “private” (23.7%), “could be done by myself” 
(22.0%), and because it would be “easy” (18.9%) (refer to Table 5.4). The main reasons 
that women reported that they would not like the self-collection process is because they 
would “not be sure they did it right” (66.5%) and that it would be “painful” (20.8%). Ten 
women (2.5%) reported that they did not like the idea of self-collecting a sample at home. 
Twenty-eight percent of women reported that they would prefer to collect a sample at 
home next time they needed to be screened, compared to 40.5% who would prefer to 
have a routine pelvic exam and Pap smear performed by a clinician.  Under the 
hypothetical scenario of receiving a negative HPV test result after submitting a self-
collected sample, 25.4% of women reported that they would feel comfortable not seeing a 
doctor, compared to 19.2% of women who would not, with 47.7% reporting “maybe.”   
5.6 Discussion 
Using Facebook as a recruitment tool to invite women to participate in at-home 
self-collected HPV testing showed promising results.  More than half (54.5%) of women 
who were invited to self-collect a vaginal sample for HPV testing participated in this 
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study, and 92.5% of these women successfully completed and returned a sample for 
testing.  A high prevalence (17.8%) of HPV was detected using self-collection, which is 
comparable to studies of self-collection that have been conducted in controlled healthcare 
settings (18.4%) and to that of community-based screening in rural settings (17.6%) 
providing further evidence of the performance of self-collected sampling in non-clinical 
settings [163, 172].  The vast majority (87.1%) of women who completed the kit found 
self-collection to be easy to do.  These results indicate that women who are recruited on 
the Internet can and will participate in HPV screening outside of traditional healthcare 
settings.  If HPV vaccination uptake continues to increase among young women, this at-
home screening method may provide an alternative, cost-effective method for screening 
in an era with an extremely low incidence of cervical cancer.    
Women who self-collected a vaginal sample reported more favorable attributes of 
self-collection compared to women who only participated in the online survey, such as 
ease of sampling (87.1% vs. 18.9%), no pain during sampling (72.6% vs. 5.6%), and lack 
of embarrassment (67.7% vs. 12.9%). These findings are consistent with studies of self-
collected samples for Chlamydia trachomatis screening which have shown that home 
testing is a strong facilitating factor for participating in testing and a more acceptable 
method than clinician-collected samples among young women [173-174]. This finding is 
encouraging, as it demonstrates that self-collection is not only acceptable to women, but 
also a viable solution to collect a sample without invoking the time and cost of visiting a 
healthcare professional.  However, it is important to note that women would likely 
benefit if they were to receive an introduction to self-collection methods within a clinical 
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setting and then proceed to use self-collection methods at the next recommended 
screening interval.  This subsequent screening “visit” could then be managed with ease 
using online reminders and strategies to complete home self-collection at the appropriate 
time.  
Recruiting women via the Internet is highly cost-effective and time efficient. Of 
the women who participated in self-collected HPV testing, 37.5% responded to the first 
study invitation and requested a kit within 48 hours of receiving the invitation. As was 
previously shown, the average advertising cost to recruit a person via Facebook was 
$1.36 (Manuscript 1).  This approach to data collection may also be particularly well 
suited to surveillance studies that wish to identify risk factors associated with sensitive 
topics as other studies have shown that internet surveys can elicit responses on sensitive 
topics and also avoid bias associated with in-person interviews [105, 107].  
 One limitation of this pilot study is that subjects were recruited from a previous 
study and represent a small convenience sample of women in the Twin Cities 
Metropolitan Area.  Thus, the women who participated in the acceptability survey or who 
returned a self-collection kit may not be representative of the general population.  
However, the objective of this study was to determine if the study protocol and 
procedures (i.e. internet recruitment) were acceptable to women and if they could be 
applied to more generalized populations to increase cervical cancer screening.  
 Another limitation of this study is that self-collected HPV tests are not approved 
for use in any age group.  Further, HPV DNA testing in women younger than 30 years 
old is not recommended in clinical practice although the cobas HPV test (Roche 
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Molecular Systems, Incorporated, Pleasanton, California) just recently received FDA 
approval for use in women aged 25 years and older [159].  Thus, the acceptability of 
HPV DNA testing in this younger, more technologically proficient population may not 
translate to populations of women who are currently in their late 30s and early 40s for 
whom HPV DNA testing (in conjunction with cervical cytology) is a recommended 
screening practice for cervical cancer prevention.  However, the guidelines for cervical 
cancer screening have evolved quickly as new technologies have emerged and make it 
plausible that self-collected HPV DNA testing may be used in the future to detect and 
monitor HPV infections in high-risk young women who do not participate in traditional 
screening and among this population of women as they age.  In addition, it has been 
estimated that screening with HPV DNA testing followed by cytology in younger women 
who have been vaccinated against HPV to be more cost-effective than the current 
screening practices [175].  Therefore, accessing these younger populations for screening 
using HPV DNA testing may not only prevent disease, but it may also result in lower 
costs and increased cervical cancer screening. 
 In conclusion, the results from this study suggest that recruiting young adults via 
the Internet to participate in HPV testing is highly efficient and cost-effective.  In 
addition, self-collected screening was found to be acceptable and favorable among 
women aged 21 to 30 years.  Collectively, these findings suggest that this recruitment and 
screening approach may be used to facilitate targeted screening among high-risk sub-
populations, including under-screened and underprivileged women, to reduce the burden 
of HPV disease. Future work is needed to examine how at-home testing can be used in 
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conjunction with traditional screening practices to optimize screening intervals and 
reduce unnecessary healthcare costs.     
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Figure 5.1. Manuscript 3 study flowchart.  
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Table 5.1. Selected characteristics of study participants. 
  
Self-Collection Arm  
(n=62) 
Acceptability Survey Arm  
(n=130) 
  N % N % 
Age, in years          
20-22 19 22.0 42 32.1 
23-24 17 19.7 45 34.4 
25-27 15 17.4 22 16.8 
28-30 11 12.7 22 16.8 
Mean age  24.4 2.6 (SD) 24 2.7 (SD) 
Race     
White 54 87.1 103 78.6 
Black 3 4.8 8 6.1 
Asian 1 1.6 8 6.1 
Am. Indian/AL native 3 4.8 4 3.1 
Other 1 1.6 8 6.1 
Education     
Some High School 0 0.0 1 0.8 
High School Graduate 2 3.2 7 5.4 
Some College or Tech. School 11 17.7 41 31.5 
College Graduate 41 66.1 62 47.7 
Graduate School 8 12.9 19 14.6 
Sexual Orientation     
Heterosexual 55 88.7 119 90.8 
Homosexual, gay, or lesbian 2 3.2 2 1.5 
Bisexual  4 6.5 8 6.1 
Choose not to answer 1 1.6 2 1.5 
Ever had HPV vaccine         
Yes 43 69.4 90 70.9 
No  18 29.0 35 27.6 
Don’t know 1 1.6 2 1.6 
Income     
Under $15,000 16 27.1 33 25.4 
$15,000 to $24,999 5 8.5 17 13.1 
$25,000 to $34,999 9 15.3 14 10.8 
$35,000 to $49,999 9 15.3 19 14.6 
$50,000 to $74,999 10 16.9 18 13.8 
$75,000 to $99,999 4 6.8 6 4.6 
More than $100,000 6 10.2 11 8.5 
Prefer not to answer - - 6 4.6 
Don't know - - 6 4.6 
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Table 5.2. Comparison of those who enrolled in the study to participate in self-collection 
to those who did not enroll in the study. 
 
  
Enrolled in  
Self-collection 
(n=67) 
Did not Enroll  
(n=56) 
  N % N % 
Age, in years          
20-22 21 31.3 19 33.9 
23-24 18 26.9 22 39.3 
25-27 17 25.4 7 12.5 
28-30 11 16.4 8 14.3 
Mean age  24.4 2.6 (SD) 23.5 2.7 (SD) 
Race         
White 57 90.5 44 78.6 
Black 2 3.2 4 7.1 
Asian 3 4.8 4 7.1 
Am. Indian/AL native 3 4.8 0 0.0 
Other 1 1.6 4 7.1 
Hispanic/Latino         
Yes 1 1.5 1 1.8 
No 65 98.5 56 98.2 
Education         
Some High School 0 0.0 0 0.0 
High School Graduate 2 3.0 1 1.8 
Some College or Tech. School 12 17.9 18 32.1 
College Graduate 44 65.7 28 50.0 
Graduate School 9 13.4 9 16.1 
Vaccinated against HPV         
Yes 46 68.7 33 61.1 
No 20 29.9 18 33.3 
Don't know 1 1.5 3 5.6 
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Table 5.3. Comparison of those who enrolled in the study to participate in the 
acceptability survey to those who did not enroll in the study. 
 
  
Enrolled in the  
Acceptability Survey  
(n=130) 
Did not Enroll  
(n=100) 
  N % N % 
Age, in years          
20-22 42 32.3 40 40.0 
23-24 45 34.6 32 32.0 
25-27 22 16.9 14 14.0 
28-30 21 16.2 14 14.0 
Mean age  24.0 2.7 (SD) 23.4 2.7 (SD) 
Race         
White 103 79.2 79 79.8 
Black 8 6.2 10 10.1 
Asian 7 5.4 5 5.1 
Am. Indian/AL native 4 3.1 0 0.0 
Other 8 6.2 5 5.1 
Hispanic/Latino         
Yes 2 1.6 5 5.0 
No 125 98.4 95 95.0 
Education         
Some High School 1 0.8 0 0.0 
High School Graduate 7 5.4 4 4.0 
Some College or Tech. School 41 31.5 40 40.0 
College Graduate 62 47.7 43 43.0 
Graduate School 18 13.8 13 13.0 
Vaccinated against HPV         
Yes 89 70.6 63 63.6 
No 35 27.8 35 35.4 
Don't know 2 1.6 1 1.0 
 
  70 
 
Table 5.4. Acceptability and trust of self-collected HPV DNA screening by study arm.  
 
  
Self-Collection 
Arm 
(n=62) 
Acceptability 
Survey Arm 
(n=130) 
  N  % N  % 
Likes         
It was easy 54 87.1 75 18.9 
It was not painful 45 72.6 22 5.6 
I could do it by myself 52 83.9 87 22.0 
It was private 53 85.5 94 23.7 
It was not embarrassing 42 67.7 51 12.9 
I didn’t have to undress in front of a doctor 35 56.5 52 13.1 
Nothing, I didn't like the s/c process 2 3.2 10 2.5 
Dislikes         
Not sure I did it right 35 56.5 115 66.5 
It was painful or physically uncomfortable 5 8.1 36 20.8 
I didn’t like touching myself 1 1.6 5 2.9 
It was embarrassing 0 0.0 1 0.6 
I felt alone 0 0.0 - - 
Nothing, I liked the s/c process 26 41.9 16 9.2 
Preferred Method at next screening         
Pelvic Exam and Pap smear by doctor 15 24.2 53 40.5 
Self-collect sample at home by myself 16 25.8 37 28.2 
Prefer to do both 22 35.5 22 16.8 
I don't like either one 1 1.6 7 5.3 
I don't know 7 11.3 10 7.6 
I prefer not to respond 1 1.6 1 0.8 
Hypothetical situations         
Negative Result, comfortable not seeing doctor         
Yes 16 25.8 33 25.4 
No 19 30.6 25 19.2 
Maybe 25 40.3 62 47.7 
I don't know 2 3.2 10 7.7 
Positive Result, notification         
Letter  23 37.1 25 19.2 
e-mail 15 24.2 47 36.2 
Phone call 23 37.1 54 41.5 
I don't know 1 1.6 4 3.1 
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Chapter 6. Conclusions and Implications for Future Research  
6.1 Overview 
 Research describing the uptake and geographic variability in the human 
papillomavirus (HPV) vaccine is limited and has relied on data collected from large 
national surveillance programs. The overarching goal of this dissertation was to estimate 
the uptake of the HPV vaccine at the ZIP code level and to determine if uptake varied 
geographically. This dissertation also aimed to determine if online recruitment and at 
home screening methods would be acceptable to women.  Each manuscript investigated a 
different aspect of HPV vaccination and cancer screening in the Twin Cities Metropolitan 
Area.     
 In Manuscript 1, our aims were to (1) demonstrate the feasibility and cost-
effectiveness of recruiting men and women for health research through the Internet, and 
(2) estimate the prevalence of HPV vaccination among men and women in the Twin 
Cities Metropolitan Area.  We recruited men and women via a targeted Facebook 
advertisement campaign to complete an online survey about HPV vaccination practices.  
Of the 2,079 men and women who responded to the Facebook advertisements and visited 
the study website, 1,003 (48.2%) enrolled in the study and completed the survey. The 
average advertising cost per completed survey was $1.36.  Among those who reported 
their ZIP code, 881 out of 972 (90.6%) of the participants lived within the a priori 
geographically defined study area.  Receipt of ≥1 dose of HPV vaccine was reported by 
65.6% of women, and by 12.5% of men. This study showed that recruiting a 
representative sample of young men and women based on county and zip code location to 
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complete a survey on HPV vaccination uptake via the Internet was a cost-effective and 
feasible strategy.  This study also highlighted the need for local estimates to assess the 
variation in HPV vaccine uptake, as these estimates differed considerably from those 
obtained using survey data that is aggregated to the state (53.8% for young women and 
20.8% for young men) or national level (34.5% for women and 2.3% for men).  
 In Manuscript 2, our aim was to describe and evaluate the distribution of HPV 
vaccination uptake by ZIP code in the Twin Cities Metropolitan Area.  We examined the 
geographic variation in HPV vaccine uptake using ZIP code level data from 760 
individuals nested within 99 ZIP codes residing within a 25-mile radius of downtown 
Minneapolis, Minnesota. We employed proper spatial CAR models, which account for 
spatial dependence, in order to estimate factors associated with receipt of HPV 
vaccination. HPV vaccination was found to exhibit strong spatial dependence 
( ). Accounting for spatial dependence, older age, male gender, and liberal 
political preference were found to be significant predictors of HPV vaccination.  This 
study highlights the need to account for spatial dependence when looking at geographic 
variation in HPV vaccination. This study also underscores the need for more detailed data 
collected at the local level as ZIP code level patterns of HPV vaccine receipt were found 
to differ significantly from aggregated state and national patterns. 
 In Manuscript 3, our aim was to obtain self-collected vaginal samples for HPV 
testing from women recruited on the Internet to determine the feasibility of self-collected 
screening in this population.  We recruited a total of 197 women, with 130 completing an 
online survey about self-collection and 67 participating in self-collection. Of the 67 
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women who were sent kits, 62 (92.5%) were returned for testing. Women who self-
collected a sample reported more favorable attributes of self-collection compared to 
women who only participated in the online survey. A high prevalence of HPV infection 
was demonstrated (17.8% were infected with at least one type of HPV) among women 
recruited via the internet. Online recruitment and at home screening methods were shown 
to have the potential to engage women in screening by offering an approach that might be 
more acceptable to women of different backgrounds.   
6.2 Significance of Findings 
 Results from this dissertation are important for several reasons. Results suggest 
that national and state surveillance programs that estimate HPV vaccine uptake do not 
accurately depict what occurs at a local level.  This implies that recommendations and 
policies at these aggregate levels are also likely to overlook patterns of vaccine uptake 
that occur more locally and may result in continued vaccine disparities. These results also 
suggest that specific locations can (and should) be identified in order to maximize future 
intervention and vaccination strategies designed to reduce HPV-associated disease. These 
results also demonstrate that using the Internet is an efficient and feasible approach to 
collect public health data, particularly for sensitive or personal information.  In addition, 
these results suggest that online recruitment and screening approaches may be a viable 
solution to facilitate targeted screening among high-risk sub-populations, including 
under-screened and underprivileged women, to reduce the burden of HPV disease. 
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6.3 Strengths and Limitations 
 Several strengths of this dissertation should be noted. First, this dissertation is the 
first to examine receipt of the HPV vaccine, cancer screening practices, and 
intentions/barriers to these health services within a representative study sample.  Second, 
we collected data on HPV vaccine uptake by ZIP code, which is more detailed (i.e. higher 
geographical resolution) than what has been done previously in other studies. Third, this 
dissertation contains the first analysis to examine geographic patterns in HPV vaccine 
uptake while accounting for spatial dependence. Fourth, this dissertation includes the first 
Internet-based strategy to engage women in at-home cancer screening.   
 The dissertation also has several limitations.  First, the cross-sectional survey 
design limited our ability to determine trends in vaccination and to identify causal 
relationships. Future research should collect data at several time points in order to address 
this issue. Second, all survey responses were self-reported by persons over the Internet 
and it is possible that survey responses were subject to under or over-reporting. However, 
other Internet-based studies have shown increased self-disclosure and reporting with 
online surveys, which may reduce potential response biases (e.g. interviewer bias or 
social desirability) [19, 21]. Additionally, there was no fail proof method to ensure that 
survey responses were unique and there remains a small probability that some 
participants responded more than once. 
 Another limitation is that the spatial analyses (Manuscript 2) were conducted at 
the ZIP code level and assume a common ZIP code level effect, such that within-ZIP 
code differences may be masked.  However, ZIP codes have less variability in terms of 
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land area and population size than counties and states and may be more appropriate in the 
context of HPV vaccine uptake. Furthermore, to our knowledge, this dissertation 
examined HPV vaccination at the smallest areal unit thus far.    
 Another limitation of this dissertation is that self-collected HPV tests are not 
approved for use in any age group.  Further, HPV DNA testing in women younger than 
30 years old is not recommended in clinical practice although the cobas HPV test recently 
received FDA approval for use in women aged 25 years and older [159].  Thus, the 
acceptability of HPV DNA testing in this younger, more technologically proficient 
population may not translate to populations of women who are currently in their late 30s 
and early 40s for whom HPV DNA testing (in conjunction with cervical cytology) is a 
recommended screening practice for cervical cancer prevention.  However, the guidelines 
for cervical cancer screening have evolved quickly as new technologies have emerged 
and make it plausible that self-collected HPV DNA testing may be used in the future to 
detect and monitor HPV infections in high-risk young women who do not participate in 
traditional screening and among this population of women as they age.  In addition, it has 
been estimated that screening with HPV DNA testing followed by cytology in younger 
women who have been vaccinated against HPV to be more cost-effective than the current 
screening practices [175].  Therefore, accessing these younger populations for screening 
using HPV DNA testing may not only prevent disease, but it may also result in lower 
costs and increased cervical cancer screening. 
 Finally, results from this dissertation may not be generalizable beyond the Twin 
Cities Metropolitan Area. Notably, the characteristics of the SMASH study population 
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were similar to those of the source population.  An exception however, was that our study 
population was more educated than the general population in the Twin Cities 
Metropolitan Area which may be due to the large number of colleges and universities in 
this area.  However, it cannot be ruled out that people with lower education were less 
likely to access Facebook and view the advertisements although other studies have shown 
that lower income and less educated participants are as likely to participate in Internet-
based research studies as those who with higher incomes and higher levels of education 
[26, 35-36].   
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